Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer accounting for approximately 25-30% of all childhood malignancies. Despite much investigation, the causes of the disease are not yet fully understood. Like many other cancers, ALL is considered to be a complex disease determined by a combination of genetic and environmental factors.
The glutathione S-transferase (GST) are a family of detoxifying enzymes involved in the metabolism of numerous environmental carcinogens, it includes several loci with well-characterized polymorphisms. The genes coding for GSTT1 and GSTM1 exhibit a deletion polymorphism that in case of homozygosity leads to the absence of proteins. 1 This is a fairly common genotype in humans, with 50% of Caucasians being homozygous for null GSTM1, and 20% homozygous for null GSTT1. 2 The GSTP1 gene displays a polymorphism (1578 A4G; NCBI dbSNP: rs1695) that causes a change in amino-acid sequence at codon 105 (Ile105Val) which has been suggested to confer different catalytic activity. 3 Conflicting data exist on the association between the risk for childhood ALL and GSTs polymorphism. 4 In order to contribute to determine whether GST polymorphism may have any influence on pediatric ALL susceptibility, we study the GSTT1, GSTM1 and GSTP1 genotypes in a large cohort of Italian children with ALL and compared it with that observed in normal controls. All the 509 children (ageo18 years) diagnosed with ALL and registered in the AIEOP ALL 95 study between May and December 1996 were considered eligible for this study. Of these patients, 353 (69%) were eligible for genotyping because of the availability of biological material. Controls, all Italian, were chosen among patients admitted to selected institutions because of traumas, acute infectious episodes, or minor surgical procedures. They were matched for sex, age group (0-6; 7-10; 11-18) and area of Table 1 Distribution of GSTM1, GSTT1 and GSTP1 genotypes and their association with clinical and biological features of patients 
Letters to the Editor residence (Northern, Central, Southern Italy and Sardinia). Written informed consent to the study was obtained in accordance with the Helsinki declaration of Principle. Genotyping of leukemic patients was performed on DNA extracted from bone marrow samples taken at diagnosis or, if not available, from samples taken at any time during follow-up. DNA extracted from peripheral blood was used for healthy controls. Genotypes for GSTM1 and GSTT1 were determined according by Chen et al. 5 As it is not possible to distinguish between heterozygote and homozygote for GSTM1 and GSTT1, individuals are divided in two groups namely, 'present' (with one or two allele) and 'null' (both allele deleted); for this reason, we could not calculate if the distribution of GSTT1 and GSTM1 genotypes was in Hardy-Weinberg equilibrium. GSTP1 analysis was performed by evaluating the genotype at codon 105, according to Harries et All tests were two-sided and P-value less than 0.05 has been considered as statistically significant. Crude odds ratios (OR) were also calculated and given with 95% confidence intervals (CI).
Distribution of GST genotypes was examined according to sex, age at diagnosis, WBC count at diagnosis, B-or T-lineage disease, and presence of CNS disease. As shown in Table 1 no differences were found among the various subgroups. The outcome of the leukemic population described here was similar to that of the 1360 patients enrolled in the AIEOP ALL 95 study, 7 showing that no selection bias influenced the enrollment of patients in present study.
Genotype analysis was successfully performed in all cases (n ¼ 353) for GSTT1 and GSTM1 and in only 323 cases (91.5%) for GSTP1 genes.
Analysis of GSTM1 and GSTT1 genotypes showed no significant differences between normal controls and ALL patients in the distribution of both GSTT1 null (18 vs 14%, P ¼ 0.19; OR 0.82, 95% CI 0.61-1.10) and GSTM1 null (52 vs 47%, P ¼ 0.10, OR 0.71, 95% CI 0.47-1.07). Also the frequency of GSTP1 polymorphisms was not different in controls and cases; in fact it was 53 vs 50% for Ile/Ile, 38 vs 40% for Ile/Val and 9 vs 10% for Val/Val, (P ¼ 0.61, OR 1.14, 95% CI 0.68-1.92) ( Table 2 ). The frequencies of GSTP1 Val allele did not differ in the two populations: it was 27.9% in controls and 29.9% in cases (P ¼ 0.40, OR 1.10, 95% CI 0.87-1.40) (data not shown).
We also investigated whether the combination of one, two or all three putative high-risk genotypes could increase the risk of ALL. The individuals without any of the risk elevating genotypes were considered as reference group for statistical analysis. Our results showed no differences among patients having one, two or three putative high-risk genotypes as reported in Table 3 . This is the second largest study on GSTT1 and GSTM1 and the largest one on GSTP1 genotypes in pediatric ALL and suggests that these polymorphisms do not correlate with susceptibility to childhood ALL.
Several studies reported conflicting results on the role of GST polymorphisms in the etiology of childhood leukemia. In a recent review, a meta-analysis of 30 published case-control studies on the effect of GST polymorphisms and the risk of acute lymphoblastic and myeloid leukemia was performed. 4 This review suggests that GSTM1 and GSTT1 but not GSTP1 polymorphisms appear to be associated with a modest increase in the risk of ALL. Only a few of these studies are focused on childhood ALL and in Table 2 Distribution of GSTM1, GSTT1 and GSTP1 genotypes in patients and controls found GSTT1 and GSTM1 gene frequencies similar to those of controls, but they do not confirm the data on black children. In contrast a Canadian study on 177 cases showed an increased frequency of GSTM1 null genotype in children with ALL. 9 A smaller number of studies have been reported on the possible influence of GSTP1 genotype on childhood ALL. All of them had negative results; only one on 278 cases reported a role of GSTP1 in the susceptibility to childhood ALL in individuals carrying the variants Val105/Ala114 but did not shown clear results on the role of each variant. 10 In these studies, positive results were obtained in a French-Canadian population, suggesting that the influence of GSTs on the risk of leukemia could differ among populations, or a different exposure could be involved in leukemogenesis.
Several factors must be considered in the design of a reliable case-control study. A large sample size with an adequate power is one of the most important factors. The choice of the control population is also crucial because the possible different exposure to environmental toxicants should be considered. All these factors were taken in account in our study and, in order to rule out geographical differences in genetic backgrounds and in environmental exposure to carcinogens, the normal controls were matched not only for gender and age, but also for geographical area of residence. This is the first study that takes into consideration also the residence area as a criterion for the selection of controls.
In addition this is the second study after that of Davies et al 8 that considered the possible influence of genotype on the patients' clinical characteristics, confirming the lack of association between ALL subtype and GST polymorphism.
In conclusion, this study represents one of the largest studies on GSTT1 and GSTM1 genotypes, and the largest study on GSTP1 genotypes in children with ALL. Our data do not support a role of GST genotypes in genetic susceptibility to ALL. Our findings, although negative, contribute to give a definitive answer to the question on the role of GST genotype in childhood ALL etiology at least in the Caucasian population.
Expression and mutation status of candidate kinases in multiple myeloma Kinase hyperactivity often results in deregulation of cellular pathways involved in proliferation and survival. In multiple myeloma (MM), for example, the translocation of FGFR3, a receptor tyrosine kinase (RTK), to the immunoglobulin heavy chain locus is found in 15% of patients. FGFR3 mutations, activating the receptor, are found in both primary patient samples and cell lines, supporting the role of FGFR3 signaling in the pathogenesis of the disease. In recent years, several other kinases have also been reported to be somatically mutated in hematologic and solid organ malignancy. Furthermore, mutated kinases are ideal targets for therapeutics. These observations have led us (and others) to attempt kinome-wide sequencing in
